Hydroxyurea treatment for chronic myeloid leukemia during pregnancy

CELİLOĞLU M., ALTUNYURT S., Undar B.

ACTA OBSTETRICIA ET GYNECOLOGICA SCANDINAVICA, cilt.79, sa.9, ss.803-804, 2000 (SCI-Expanded) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 79 Sayı: 9
  • Basım Tarihi: 2000
  • Doi Numarası: 10.1034/j.1600-0412.2000.079009803.x
  • Dergi Adı: ACTA OBSTETRICIA ET GYNECOLOGICA SCANDINAVICA
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Sayfa Sayıları: ss.803-804
  • Anahtar Kelimeler: chronic myeloid leukemia, hydroxurea treatment, white blood cell count, CHRONIC MYELOGENOUS LEUKEMIA
  • Dokuz Eylül Üniversitesi Adresli: Evet

Özet

The incidence of chronic myeloid leukemia (CML) associated with pregnancy is estimated to be 1/75,000. Several types of treatments have been used for CML during pregnancy. These are cytotoxic drugs, alpha-interferone, splenic irradiation (with shielding of the uterus) and leukapheresis. Hydroxyurea is a cytotoxic drug that inhibits the synthesis of DNA and can be used both in the chronic and accelerated phases of CML (1).